Sat.Oct 15, 2022 - Fri.Oct 21, 2022

article thumbnail

How to evolve artificial intelligence models alongside societal needs

MedCity News

As society becomes more open to and reliant on these tools, it is the responsibility of technology companies, especially those tasked with assisting people’s mental health, to build and maintain artificial intelligence and machine learning models that adapt alongside societal needs.

145
145
article thumbnail

Tackling immune-mediated disease with CAR Tregs

European Pharmaceutical Review

In recent years there has been significant development within the cell therapy field, as chimeric antigen receptor (CAR) T-cell therapy demonstrated an ability to transform the treatment of patients with haematological malignancies. Recognising the potential of CAR T cells to act as highly targeted therapeutics, several biotechnology companies – including Sangamo Therapeutics – have established development pipelines of CAR T regulatory cells (Tregs) that aim to tackle immune?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Episode 100 – Value Based Care, Data and Scale with Joseph Schulman, Senior VP Enterprise Data and Chief of Information Intelligence

Medical Device Success

Reading time: 2 – 4 minutes. 100 episodes! Wow! Hard to believe. Over 64,000 cumulative downloads. Thank you for all your support. And….you will have to keep listening because there is a lot more to share with you. Today we go back to value-based care from the providers viewpoint. Joseph Schulman is back for the second time. Joe is the Senior Vice President Enterprise Data and Chief of Information Intelligence at Northwell Health.

article thumbnail

Kite’s Yescarta to receive European marketing authorisation

PharmaTimes

First treatment in 30 years to improve second-line treatment of DLBCL

Marketing 126
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

In midterm speeches, President Biden focuses on Rx drug costs to cut inflation

MedCity News

President Biden continues to center his pre-midterm speeches around the issue of prescription drug costs, […].

article thumbnail

CHMP recommends Pluvicto® for treating advanced prostate cancer

European Pharmaceutical Review

Novartis announced that The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Pluvicto ® radioligand therapy for treatment of patients with prostate cancer. Pluvicto combines a targeting compound (ligand, in this case directed to PSMA) with a therapeutic radioisotope (in this case lutetium-177).

Medicine 124

More Trending

article thumbnail

AlzeCure gets new Alzheimer's abstract accepted

PharmaTimes

Therapy is based on ACD856's indicative disease modifying effects against the condition

126
126
article thumbnail

Endpoint security: The medicine required to cure healthcare’s cybersecurity woes

MedCity News

The healthcare industry has been reported as the second most targeted industry from cyberattacks. Following the business […].

Medicine 136
article thumbnail

5 impactful drug trial failures from the last year

PharmaVoice

Major recent trial flops and what they mean for companies, patients and the industry.

Patients 119
article thumbnail

Frontiers Health 2022 – day 2

pharmaphorum

And the LIVE coverage continues as we head into Day Two… This day is set to hold even more points of interest, with the demonstration ‘CX innovation: building experiences that work for customers’ (moderated by Healthware Group’s global head of digital strategy and customer engagement Yannick Valenti), as well as the masterclass ‘How to maximise learning science to affect behaviour change’ with Meducate Global’s president, Lawrence Sherman, and MD of Healthware MedComms & SWM, Francis M

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Parliament square set for ME research demonstration

PharmaTimes

Demonstrators will demand hundreds of millions of pounds ‘missing’ from ME research

123
123
article thumbnail

Here’s 40 years of cardiac advancements that few know about

MedCity News

With so much supporting data and real-world success, it is time for catheter ablation to become a routine treatment option for patients suffering from arrhythmias.

Patients 136
article thumbnail

Lilly agrees to acquire gene therapy developer Akouos for $610m

Pharmaceutical Technology

Eli Lilly and Company has signed a definitive agreement for the acquisition of all outstanding shares of precision genetic medicine firm Akouos for a total deal value of up to nearly $610m or up to $15.50 for each share in cash. The deal comprises an acquisition value of $12.50 for each share in cash payable at closing along with one non-tradeable contingent value right per share (CVR) of up to another $3 in cash.

article thumbnail

Bringing the promise of immunotherapy to a broader population

pharmaphorum

When James P Allison and Tasuku Honjo were awarded the Nobel Prize for Medicine in 2018 for their discovery of cancer therapy through inhibition of negative immune regulation, it shone a light on decades of research into recruiting the immune system to fight cancer. Their success led to the discovery of an entirely new principle for cancer therapy – the field of immuno-oncology – one that is now a mainstay of cancer treatment, changing the way these diseases can be managed.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Grifols’ Tavlesse receives NICE recommendation

PharmaTimes

Therapy treats refractory chronic immune thrombocytopenia and is available across UK

119
119
article thumbnail

Eyenuk raises $26M for diabetic retinopathy screening tech

MedCity News

Eyenuk, a company that makes technology for eye screenings, raised $26 million in a Series A funding round, bringing its total funding to more than $43 million. Research shows that the company’s AI system is more accurate in detecting diabetic retinopathy than a clinical examination from a general ophthalmologist or a retina specialist.

135
135
article thumbnail

What’s keeping pharma leaders up at night

PharmaVoice

C-suite execs in the life sciences share their late-night thoughts including innovation, patient access and market factors.

Pharma 111
article thumbnail

Hookipa partners with Roche for cancer immunotherapy development

Pharmaceutical Technology

Hookipa Pharma and Roche have signed a strategic partnership and licence agreement for developing HB-700 and another undisclosed arenaviral immunotherapy. Under the deal, Hookipa will carry out research and initial clinical development through Phase Ib for HB-700 to treat KRAS-mutated cancers. On concluding this trial, Roche will gain the right to develop and market the licenced products across various indications, contingent on approval.

Pharma 111
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Apogenix’s asunercept demonstrates efficacy in COVID-19 trial

PharmaTimes

Therapy showed faster clinical recovery for combined treatment groups

113
113
article thumbnail

NeuroFlow raises $25M to scale behavioral health integration tech

MedCity News

NeuroFlow, a Philadelphia-based provider of behavioral health integration software, recently raised $25 million in growth capital. The startup differentiates itself from the sea of mental health-focused startups in the digital health world because of its ability to combine effective patient engagement technology with decision support tools for clinical staff, according to COO Adam Pardes.

Patients 135
article thumbnail

A new class of drugs with ‘huge’ potential in the fight against challenging breast cancers

PharmaVoice

Drug developers have been making headway in treating the most difficult and deadly forms of breast cancer.

111
111
article thumbnail

EC approves CAR T-Cell therapy for B-cell lymphoma

European Pharmaceutical Review

Kite announced that the European Commission (EC) has approved the use of cell therapy Yescarta ® for treatment of patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), who relapse within 12 months or are refractory to, first-line chemoimmunotherapy. The approval is based on results from the Phase III ZUMA-7 study, the largest and longest trial of a CAR T-cell therapy versus standard of care (SOC) in this patient population.

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Bayer extends elinzanetant trials to include breast cancer

pharmaphorum

Bayer has added another clinical trial to its extensive phase 3 programme for oral neurokinin antagonist elinzanetant, hoping to show that it can treat vasomotor symptoms (VMS) in breast cancer patients. Elinzanetant is already being tested in the OASIS trials for VMS associated with menopause – an indication in which Bayer is in a head-to-head race with Astellas and its fezolinetant drug candidate – and breast cancer could represent a sizeable additional patient population for the drug.

Patients 111
article thumbnail

How to improve data literacy within healthcare organizations

MedCity News

Healthcare organizations must ensure they have a data-literate workforce that is confident in using the data and is empowered in using it to make decisions. Here are some best practices that hospitals can implement to better empower their employees to make data-driven decisions.

article thumbnail

Alzheimer’s Diagnostic Test Spots Amyloid ? Exosomes in Blood

Medgadget

Researchers at Hokkaido University in Japan have developed a biomarker test for Alzheimer’s disease that detects amyloid ? binding exosomes in a blood sample. While amyloid ? plaques in the brain are characteristic of Alzheimer’s, these researchers have previously reported that amyloid ? build-up in the brain is associated with an increase in amyloid ?

Patients 106
article thumbnail

J&J reveals just how much economic turbulence is affecting Big Pharma

PharmaVoice

The healthcare giant showed pharmaceutical gains, but that's no thanks to the economic environment of persistent inflation and a strong U.S. dollar.

Pharma 105
article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

Immunotherapy shows benefits for hospitalised COVID-19 patients

European Pharmaceutical Review

Apogenix , a biopharmaceutical company developing next generation immunotherapeutics, announced that asunercept showed statistically significant benefits for hospitalised COVID-19 patients in the ASUNCTIS trial. Apogenix’s lead immunotherapy candidate, asunercept is a fully human fusion protein, consisting of the CD95 receptor and an IgG1 antibody. It is being developed for the treatment of solid tumours, haematological malignancies and viral infections such as COVID-19.

Patients 105
article thumbnail

Cancer drug biotech Enliven shifts to reverse to move forward as a public company

MedCity News

Enliven Therapeutics’ reverse merger with Imara will form a combined company with $300 million to finance clinical development of new cancer drugs. Its most advanced program is a tyrosine kinase inhibitor for chronic myeloid leukemia.

Biopharma 131
article thumbnail

Frontiers Health 2022 – day 1

pharmaphorum

Frontiers Health 2022 in Milan is LIVE! Opening Day One will be Healthware Group’s CEO and founder Roberto Ascione and WTF Health’s founder and host Jessica DaMassa. The day’s keynote addresses will include ‘The H is for humanity’ by MD of Taliossa Tony Estrella and founder and trustee of Rachel’s House Lynna Chandra, as well as ‘Creative disruption in delivering novel VR solutions in pain: evidence, teamwork, and delivery’ by Christopher Eccleston, professor of medical psychology at the U

article thumbnail

Novel CSF biomarkers signal new avenues for Parkinson’s therapeutics

Pharmaceutical Technology

A new study identifies a novel cerebrospinal fluid biomarker for Parkinson’s disease, expanding the scope of possible drug targets. Last week, Nature magazine published a paper detailing an in-situ study of Parkinson’s disease (PD), showing protein structural changes in cerebrospinal fluid (CSF) between healthy individuals and Parkinson’s patients. There is potential that these structural changes could allow for a new method of differentiating different disease subtypes, thus expanding the scope

Patients 105
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time